SCHEMBL4154574

SCHEMBL4154574

CCOC(=O)c1nc(Cl)ccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 1/20 0.57
KMT2A Q03164 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.56
MAPT P10636 3/20 0.54
LMNA P02545 1/20 0.54
GAA P10253 1/20 0.53
NPC1 O15118 1/20 0.52
TP53 P04637 1/20 0.52
XBP1 P17861 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TLR9 Q9NR96 1/20 0.52
GLP1R P43220 1/20 0.48
TARBP2 Q15633 1/20 0.48
CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4162744 0.86 KDM4E (0.48) ALDH1A1KDM4EKMT2AL3MBTL1MAPT
SCHEMBL26281309 0.86 ALDH1A1 (0.52) ALDH1A1KDM4EKMT2AL3MBTL1MAPT
SCHEMBL6306356 0.85 TSHR (0.50) ALDH1A1KDM4EKMT2AMAPTNPC1
SCHEMBL8103564 0.85 CYP1A2 (0.59) ALDH1A1MAPTNPC1TP53XBP1
SCHEMBL16061031 0.83 ALDH1A1 (0.50) ALDH1A1KDM4EKMT2AL3MBTL1MAPT
SCHEMBL7453018 0.83 ALDH1A1 (0.46) ALDH1A1KDM4EKMT2AL3MBTL1MAPT
SCHEMBL31284830 0.83 TARBP2 (0.49) ALDH1A1KDM4EKMT2AL3MBTL1MAPT
SCHEMBL14966295 0.83 ALDH1A1 (0.50) ALDH1A1KDM4EKMT2AL3MBTL1MAPT
SCHEMBL31283683 0.83 ALDH1A1 (0.46) ALDH1A1KDM4EKMT2AL3MBTL1MAPT
SCHEMBL20098657 0.83 TARBP2 (0.49) ALDH1A1KDM4EKMT2AL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114127066-A Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase 爱杜西亚药品有限公司 2022-03-01 CN disclosed
CN-109952300-B 5-or 8-substituted imidazo [1,5-a ] pyridines 百济神州有限公司 2022-01-18 CN disclosed
CN-107531693-B 5 or 8-substituted imidazo [1, 5-a ] pyridines as indoleamine, tryptophan dioxygenase inhibitors 百济神州有限公司 2021-07-06 CN disclosed
US-10882856-B2 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases BEIGENE, LTD. (KY) 2021-01-05 US disclosed
US-10882856-B2 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases BEIGENE, LTD. (KY) 2021-01-05 US disclosed
EP-3280715-B1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE LTD (KY) 2020-11-25 EP disclosed
US-10647714-B2 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases BEIGENE, LTD. (KY) 2020-05-12 US disclosed
US-10647714-B2 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases BEIGENE, LTD. (KY) 2020-05-12 US disclosed
CN-110872289-A Novel 8-substituted imidazo [1,5-a ] pyridines as IDO1 and/or TDO inhibitors 百济神州(北京)生物科技有限公司 2020-03-10 CN disclosed
US-20190284184-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1,5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2,3-DIOXYGENASES BEONE MEDICINES I GMBH (CH) 2019-09-19 US disclosed
US-20180072716-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEONE MEDICINES I GMBH (CH) 2018-03-15 US disclosed
US-20180072716-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEONE MEDICINES I GMBH (CH) 2018-03-15 US disclosed
WO-2016161960-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE, LTD. (KY) 2016-10-13 WO disclosed
US-9006257-B2 Bicyclic compounds as mPGES-1 inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2015-04-14 US disclosed
WO-2013118071-A1 BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2013-08-15 WO disclosed
US-20130210844-A1 BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2013-08-15 US disclosed
WO-2013072825-A1 PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2013-05-23 WO disclosed
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed
EP-1670763-A1 CYCLOPENTENE COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-06-21 EP disclosed
WO-2005037793-A1 CYCLOPENTENE COMPOUNDS GLAXO GROUP LIMITED (GB) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10882856-B2 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases IDO1, TPH1, IDO2 ALDH1A1 621/4885KDM4E 241/4885KMT2A 1176/4885
US-20090227591-A1 Cyclopentene compounds C1R, CYP1B1, ADORA2B ALDH1A1 1534/4885KDM4E 2449/4885KMT2A 3463/4885
US-20130210844-A1 BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS PTGES, PTGS1, PTGIS ALDH1A1 163/4885KDM4E 3318/4885KMT2A 3771/4885
US-10647714-B2 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases IDO1, TPH1, IDO2 ALDH1A1 466/4885KDM4E 411/4885KMT2A 1453/4885
US-20190284184-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1,5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2,3-DIOXYGENASES IDO1, TPH1, IDO2 ALDH1A1 434/4885KDM4E 342/4885KMT2A 1489/4885
US-20180072716-A1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES IDO1, TPH1, IDO2 ALDH1A1 440/4885KDM4E 490/4885KMT2A 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.